Sara Talbot

BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors

H. Ditzel, C. Tornador, G. Fabbri, 2023, Molecular Cancer.

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

S. Barry, C. Rooney, J. Urosevic, 2023, NPJ breast cancer.

Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models

A. Lau, Zena Wilson, E. Cadogan, 2023, Cancers.

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment

M. Cobbold, F. Calero-Nieto, Zena Wilson, 2024, Nature communications.